Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
more
Stories about Pharmaindustrie
RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
moreEpitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
moreScantox Group acquires Gentronix, a world leader in genetic toxicology
Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...
moreINSIGHTEC; Charles River Laboratories International, Inc.
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
more- 2
Record financing rounds at the Munich biotech hub
One documentmore
Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
morePress release: STADA continues strong growth journey in the first half of 2024
One documentmore- 2
Cool Concept for International Logistics / Mannheim/Germany-based eutecma GmbH with Second Location in the USA
more Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
moreGermany Attracts Another Billion-Euro Pharma Project
Berlin (ots) - French pharmaceutical giant Sanofi has confirmed it will invest 1.3 billion euros to expand insulin production in the western German city of Frankfurt am Main. Sanofi says the expansion will encompass around 36,000 square meters – the equivalent of five football fields – on the company’s existing BioCampus site. It will go operational in 2029. The project is being supported by the German national ...
moreGrünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Aachen, Germany (ots) - - Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. - With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). - Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly ...
more
- 2
Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients
more - 10
Gerresheimer: New pictures available
more LAUDA DR. R. WOBSER GMBH & CO. KG
5ACHEMA 2024: LAUDA Looks Back on a Successful Exhibition
morePress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmoreBayer Collaborates with PAPACKS to Co-create Alternative-to-Plastic Packaging for Consumer Health Products
morePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmore
Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
London (ots/PRNewswire) - - Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo ...
morePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmoreGerresheimer expands capacities for Medical Systems in the USA
moreTechnische Universität München
Multi-purpose mucus - What mucins can do in medicine
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...
morePress release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmoreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
more
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
morePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmore- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
more Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
moreLTS Lohmann Therapie-Systeme AG
First product based on LTS’ Sorrel(TM) wearable drug delivery platform launched in the US
moreHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
more
Previous123456Next
